DCM
DRNA

Delpha Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Delpha Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-467
Closed -$4K – 1442
2017
Q4 		$4K Buy
+467
New +$3.44K ﹤0.01% 1388

Other funds holding DRNA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Delpha Capital Management's DRNA Position: Q1 2018 in Review

Delpha Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2018, closing a stake of 467 shares — an estimated $4K sold.

Delpha Capital Management first reported a position in DRNA in Q4 2017 and held it in 1 quarter. The position peaked at $4K in Q4 2017. 72 funds tracked by Wall St. Rank hold DRNA as of Q1 2018.

  • Delpha Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 467 Dicerna Pharmaceuticals, Inc. shares in Q1 2018, an estimated $4K.
  • Delpha Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $4K in Q4 2017.
  • 72 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.